Long non-coding RNA AFAP1-AS1 is a novel biomarker in various cancers: a systematic review and meta-analysis based on the literature and GEO datasets

摘要: // Yumin Wang 1, 2, 3, * , Yongzhen Mo Xiang Yang 1 Ruoyu Zhou 2 Zeyu Wu Yuchen He Xue Yaxian Zhong Yajun Du Hang Xiaoling Li 3 Yong 4 Guiyuan Zhaoyang Zeng Can Guo and Wei Xiong Key Laboratory of Carcinogenesis Ministry Health, Xiangya Hospital, Central South University, Changsha, Hunan, China Cancer Invasion Education, Research Institute, Hunan Nonresolving Inflammation Cancer, Disease Genome Center, The Third Department Biology, Lerner Cleveland Clinic, Cleveland, Ohio, USA These authors contributed equally to this work Correspondence to: Xiong, email: xiongwei@csu.edu.cn Guo, guocde@csu.edu.cn Keywords: long noncoding RNA, cancer, AFAP1-AS1, meta-analysis, biomarker Received: August 06, 2017      Accepted: September 23, Published: October 11, 2017 ABSTRACT Background Growing evidence indicates that AFAP1-AS1 plays an important role in various cancers, suggesting it might be a potential cancer biomarker. Materials Methods: A meta-analysis was performed using microarray data obtained via the Affymetrix Human U133 Plus 2.0 platform (found GEO database) through systematic search PubMed Web Science. pooled odds ratio (OR) hazard (HR) with 95% CI (confidence interval) were used judge value biomarkers. Results: total 30 studies included comprising 3573 patients. significantly linked overall survival (OS) (HR = 1.58; CI: 1.12–2.23) recurrence-free (RFS) 2.32, 1.68–3.19). We found risk factor prognoses lung (pooled HR: 1.54; 1.01–2.34), digestive system 1.87; 1.45–2.41) nasopharyngeal carcinoma (HR: 11.82; 5.09–27.46). also for RFS breast HR 2.90; 1.69–4.98), as well TNM stage both esophageal OR 1.90; 1.01–3.57) colorectal (OR 6.72; 1.92–23.58). associated lymph node metastasis clear cell 5.04; 2.36–10.78) distant pancreatic 11.64; 2.13–63.78). Conclusions: can serve novel molecular marker predicting tumor progression, patient prognosis different types cancers.